Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion 2 – Immunotherapy of cancer

6084 - Early peripheral T-cell responses predict oncological outcome to checkpoint immune blockade in metastatic melanoma

Date

30 Sep 2019

Session

Poster Discussion 2 – Immunotherapy of cancer

Presenters

Benjamin Fairfax

Citation

Annals of Oncology (2019) 30 (suppl_5): v475-v532. 10.1093/annonc/mdz253

Authors

B. Fairfax1, C.A. Taylor1, R.A. Watson1, I. Nassiri1, H. Fang2, E. Mahe1, R. Cooper1, S. Danielli2, V.K. Woodcock3, Z. Traill4, J.C. Knight2, M. Payne5, M.R. Middleton4

Author affiliations

  • 1 Oncology, The MRC Weatherall Institute of Molecular Medicine Oxford, OX3 9DS - Oxford/GB
  • 2 Nuffield Department Of Medicine, Wellcome Centre for Human Genetics, OX3 7BN - Oxford/GB
  • 3 Department Of Oncology, Churchill Hospital University of Oxford, OX3 7LE - Oxford/GB
  • 4 University Of Oxford Department Of Oncology, University of Oxford, OX3 7DQ - Oxford/GB
  • 5 Medical Oncology, John Radcliffe Hospital, Oxford/GB

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 6084

Background

Immune Checkpoint blockade for the treatment of metastatic melanoma is associated with highly variable clinical outcomes between individuals in terms of both oncological benefit and immune-related adverse events. Early markers of response are urgently sought. Whereas numerous intra-tumoural determinants of sensitivity to immunotherapy are known, the identification of peripheral predictors of response is limited. We aimed to characterize the CD8+ T-cell transcriptomic and clonal changes to treatment across a large cohort of patients in an effort to gain further insight into the peripheral markers of response.

Methods

We performed paired-end 75bp read RNA-sequencing to assay the peripheral CD8+ response at baseline and across multiple cycles of treatment (n = 105 patients, 69 controls, 315 separate transcriptomes). We validated identified clonal subsets indicative of response using 10X Chromium single cell sequencing (16 samples, 8 patients), flow-cytometry and targeted PCR.

Results

After adjusting for multiple testing, we identify >5,800 transcripts induced by treatment. These fall into discrete gene modules, with several markedly diverging between combination immunotherapy and anti-PD1 alone. Patients demonstrating a durable radiological response to checkpoint immunotherapy (absence of progression at 6 months) have significantly increased numbers of large peripheral CD8+ circulating clones by day 21 after treatment, compared to non-responders and controls. We replicate this observation in a separately recruited cohort. Large peripheral clones have a distinct gene expression profile, characterized by high expression of CCL5, BCL2L1and NKG7 amongst other genes.

Conclusions

We identify robust and reproducible predictors of 6 month clinical and radiological responses to immune checkpoint blockade in the transcriptomes of peripheral circulating CD8+ T-cells from metastic melanoma patients after 21 days of treatment. These observations can be used to further our understanding of determinants of patient response, and may provide a mechanism for early treatment stratification of patients with a non-favourable peripheral profile.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

Oxford Radcliffe Biobank.

Funding

Wellcome Trust, Oxford NIHR Biomedical Research Centre, Cancer Research UK.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.